Clinical trials have shown that a strategy for haploidentical transplantation based on the infusion of high numbers of T-cell-depleted hematopoietic progenitor cells and no post-transplant immunosuppression controls graft rejection and GvHD in patients with acute leukemia. Overall, event-free survival compares favorably with reports of transplants using sources of stem cells other than the matched sibling. Current studies are focussing on rebuilding post-transplant immunity to improve clinical outcomes separating GvHD from favourable donor immune responses.
INTRODUCTION
The obvious advantage of haploidentical transplantation is that almost every patient who does not have a HLA-identical donor or who urgently needs transplantation has at least one family member who is promptly available as a donor. Furthermore, the donor can be changed if the selected individual was a poor stem cell mobiliser or if optimal graft composition was not achieved. Another advantage is the benefit of natural killer (NK) cell alloreactivity and easy access to donor-derived cellular therapies after transplantation, if required. 
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+ cells/kg) ensured primary engraftment in 95% of patients with acute leukemia in the original experience of the Perugia group. [3] [4] [5] Under the fludarabine-based conditioning regimen and positive selection of the CD34 + cells by CliniMacs, both rejection and GvHD were prevented even in the absence of any further post-transplant immunosuppression. 4, 5 In high-risk leukemia patients who did not develop GvHD after an extensively T-cell-depleted mismatched transplant, one would expect an increased risk of relapse because of the lack of GvHDmediated graft-vs-leukemia (GvL) effect. An updated analysis of 255 high-risk acute leukemia patients who were transplanted in Perugia over almost 20 years showed the relapse rate was 18% in AML and 30% in ALL patients who were transplanted in any CR. The intensely myeloablative conditioning regimen could have compensated for the lack of T-cell mediated GvL effect and, in the absence of post-transplant immunosuppression, the few T cells in the graft may have exerted a subclinical GvL/GvHD effect. Furthermore, in AML, donor-vs-recipient NK alloreactivity helped prevent relapse. [6] [7] [8] [9] In an updated analysis of 154 patients with AML, transplantation from NK-alloreactive donors was associated with a significantly lower relapse rate (7% vs 36%) (P = 0.02) and better event-free survival (59% vs 33%, P = 0.05). Apart from the NK alloreactivity, 43% of AML and 30% of ALL patients who were in any CR at transplant survive event-free with a maximum follow-up of 20 years. Although patients who were in chemoresistant relapse at transplant had poor outcomes, the 18% disease-free survival (DFS) for AML patients is worth noting. Finally, all long-term survivors enjoy an excellent quality of life with no chronic GVHD. A EBMT retrospective study reported similar results with 48% event-free survival in AML patients in first CR. 10 Two remarkable observations emerged. Engraftment was promoted by the megadose of CD34 + cells, because they suppressed cytotoxic T-lymphocyte precursors directed against their own antigens (veto effect). 11, 12 A powerful GvL effect in the absence of GvHD was induced in AML patients by post-transplant generation of the donor-vs-recipient alloreactive NK cell repertoire.
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POSTTRANSPLANT IMMUNOLOGICAL RECONSTITUTION One major problem, at least in adults, which appears to be common to all T-cell-depleted transplants, was the slow recovery of the antimicrobial and antiviral responses. Because of the minimal residual T lymphocytes in the graft and in vivo ATG-linked T-cell depletion the post-transplant immunological reconstitution was delayed, thus haplo-transplant recipients remained susceptible to life-threatening opportunistic infections for several months. Overall non-relapse mortality was 36% for 145 patients in CR at transplant and 58% for 110 patients transplanted in relapse. 4, 5 Any further reduction in transplant-related mortality in T-cell-depleted haplotransplants will only be achieved by hastening post-transplant immune recovery and several groups are focussing on rebuilding post-transplant immunity to improve clinical outcomes separating GvHD from favourable donor immune responses. To hasten and improve post-transplant immune reconstitution broad repertoire donor T cells were infused with various strategies to prevent GvHD, for example, engineering with a suicide gene 13, 14 or depleting alloreactivity by means of photodynamic purging. 15 An alternative strategy might be based on adoptive immunotherapy with thymic-derived CD4 + CD25
+ regulatory T cells. 16, 17 The platform of T-cell-depleted haplo-HSCT without any post-transplant immunosuppression together with these insights from animal models prompted us to focus on adoptive immunotherapy with a high number of broad repertoire T cells, co-infused with freshly isolated CD4 + CD25 + FOXP3 + regulatory T cells. 18, 19 Lethal GvHD was suppressed and the pattern of post-transplant immune reconstitution was markedly different from standard T-cell-depleted haploidentical transplants. 18, 19 FROM POSITIVE SELECTION TO NEGATIVE DEPLETION In an innovative approach Handgretinger's group depleted the leukapheresis product of only TcR alpha/beta+ (αβ+) cells, thus retaining large numbers of effector cells such as TcRγδ+ T cells and NK cells. 20 TcRγδ+ T cells combine conventional adaptive features with direct, rapid responses against sterile stresses and a variety of pathogens. 21 Furthermore TcRγδ+ T cells appear to exert anti-leukemic activity, as they directly recognized stress-induced self Ags expressed by malignant cells. 20, 22 They are not expected to initiate GvHD as they do not recognize specific processed peptide antigens as presented on MHC molecules.
To remove TcRαβ+ T lymphocytes a biotinylated anti-TcR αβ Ab was used, followed by an anti-biotin Ab conjugated to magnetic microbeads. A 4.7 log depletion was achieved, with a median of 14 × 10 3 /kg. infused TcRαβ+ T lymphocytes. CD19+ B lymphocytes were also immuno-depleted to prevent post-transplant EBVassociated lymphoproliferative disorders. 20 Recovery of CD34+ hematopoietic progenitor cells (74%) was similar to CD34+ enrichment procedures. In Tubingen, children with advanced acute leukemia were transplanted with TcRαβ+/CD19+ depleted grafts following chemotherapy-based conditioning. Locatelli in Rome used the same method for graft processing and a TBI-based conditioning. 20 In both cohorts no post-transplant GvHD prophylaxis was given, although anti-T antibodies (OKT3 or ATG) in the conditioning exerted additional in vivo T-cell depletion of the inoculum. Very rapid full donor type engraftment occurred in all patients. Few had acute grade 1 and 2 GvHD and no patient developed chronic GvHD, confirming that TcRγδ+ T cells do not cause GvHD. Immune reconstitution was rapid in these children.
ONGOING STUDY
To determine whether the post-transplant immunological reconstitution can be improved even in adult patients, we have recently tested this approach in 16 patients with high-risk acute leukemia (12 AML, 4 ALL). Median age was 45 years (range 19-65), nine were in CR and seven in chemoresistant relapse (Table 1) . Conditioning consisted of ATG (1.5 mg/kg from day − 13 to day − 10), treosulfan (12gr/sqm from − 9 to -7), fludarabine (30 mg/ sqm from − 6 to − 2) and thiotepa (5 mg/Kg on days − 5 and − 4). No immune suppression was given after transplantation as GvHD prophylaxis; no G-CSF was administered posttransplantation. Antifungal prophylaxis included liposomal amphotericin-B (1 mg/ kg daily) from day − 5 until neutropenia ended. CMV prophylaxis was ganciclovir (10 mg/kg) from day − 9 to day − 2 followed by pre-emptive therapy.
Median infused cell doses per kilogram of recipient body weight are reported in Table 2 . All but one patient, who required a second graft from the same donor to boost hematopoietic reconstitution, achieved a full donor-sustained engraftment. Neutrophils and platelets reached respectively a mean of 1 × 10 9 /L and 25 × 10 9 /L at a median of 11 (range 9-15) and 10 (range 5-13) days. Tending to confirm our working hypothesis, there was a rapid, sustained increase in peripheral blood T-cell subpopulations. CD4 and CD8 counts reached 200/μL medianly on, respectively, days 45 (range, 19-98) and 38 (range, 13-69). Naive and memory T-cell subsets increased significantly over the first year after transplantation. B-cell reconstitution was rapid and sustained and Ig serum levels 
